C
코오롱생명과학
102940KOSDAQ기초 의약물질 제조업51.5 / 100
Reference Date: 2026-04-13
Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 2.1% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Kolon Life Science operates three business segments: Chemical, SC, and Bio. The Chemical segment, focused on pharmaceutical API production, drives revenue growth due to expanding global pharmaceutical markets and increased outsourcing of raw material production. However, the Bio segment continues to report significant losses.
Number of Employees
454people
Average Salary
60.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
29.21Industry Average 33.455.0Point
In line with industry avg
PBR
1.25Industry Average 2.035.5Point
Lower than industry avg (good)
ROE
6.81Industry Average -4.293.5Point
Well below industry avg
Debt Ratio
27.50Industry Average 6.610.0Point
4.2x industry avg (risky)
Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲29.5% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲94.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -26.1% (improving, 3yr)
Detailed News Sentiment
5 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50
- Neutral
Detailed Momentum
52-week position6.0Point
52w upper range (67%)
Current 55,700Won52-week high 70,80052-week low 24,250
1-month return2.0Point
1m -2.11% (slight drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
6 totalPositive 0Neutral 6Negative 0
- Neutral특수관계인으로부터자금차입2026-03-26
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
- Neutral대표이사변경2026-03-26
- Neutral정기주주총회결과2026-03-26
- Neutral사업보고서 (2025.12)2026-03-18